NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors

NY-ESO-1 is a 180 amino-acid human tumor antigen expressed by many different tumor types and belongs to the family of “cancer-testis” antigens. In humans, NY-ESO-1 is one of the most immunogenic tumor antigens and NY-ESO-1 peptides have been shown to induce NY-ESO-1-specific CD8+ CTLs capable of altering the natural course of NY-ESO-1-expressing tumors in cancer patients. Here we describe the preclinical immunogenicity and efficacy of NY-ESO-1 protein formulated with the ISCOMATRIX adjuvant (NY-ESO-1 vaccine). In vitro, the NY-ESO-1 vaccine was readily taken up by human monocyte-derived dendritic cells, and on maturation, these human monocyte-derived dendritic cells efficiently cross-presented HLA-A2-restricted epitopes to NY-ESO-1-specific CD8+ T cells. In addition, epitopes of NY-ESO-1 protein were also presented on MHC class II molecules to NY-ESO-1-specific CD4+ T cells. The NY-ESO-1 vaccine induced strong NY-ESO-1-specific IFN-γ and IgG2a responses in C57BL/6 mice. Furthermore, the NY-ESO-1 vaccine induced NY-ESO-1-specific CD8+ CTLs in HLA-A2 transgenic mice that were capable of lysing human HLA-A2+ NY-ESO-1+ tumor cells. Finally, C57BL/6 mice, immunized with the NY-ESO-1 vaccine, were protected against challenge with a B16 melanoma cell line expressing NY-ESO-1. These data illustrate that the NY-ESO-1 vaccine represents a potent therapeutic anticancer vaccine.

[1]  I. Davis,et al.  Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. , 2005, Blood.

[2]  T. Luft,et al.  ISCOM based vaccines for cancer immunotherapy. , 2004, Vaccine.

[3]  A. Mowat,et al.  Dendritic cell maturation enhances CD8+ T‐cell responses to exogenous antigen via a proteasome‐independent mechanism of major histocompatibility complex class I loading , 2003, Immunology.

[4]  A. Mowat,et al.  A role for dendritic cells in the priming of antigen-specific CD4+ and CD8+ T lymphocytes by immune-stimulating complexes in vivo. , 2003, International immunology.

[5]  D. Purdie,et al.  Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine , 2003, Cancer Immunology, Immunotherapy.

[6]  Danila Valmori,et al.  Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. , 2002, The Journal of clinical investigation.

[7]  Yao-Tseng Chen,et al.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.

[8]  Yao-Tseng Chen,et al.  CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Luft,et al.  Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. , 2002, Blood.

[10]  I. Mellman,et al.  Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Sjölander,et al.  Local immune responses to influenza antigen are synergistically enhanced by the adjuvant ISCOMATRIX. , 2001, Vaccine.

[12]  A. Suhrbier,et al.  Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. , 2001, Vaccine.

[13]  Gerold Schuler,et al.  Dendritic Cells as Vectors for Therapy , 2001, Cell.

[14]  N. Altorki,et al.  Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues , 2001, International journal of cancer.

[15]  S. Chen,et al.  Targeting dendritic cells to enhance DNA vaccine potency. , 2001, Cancer research.

[16]  A. Suhrbier,et al.  Immune responses to ISCOM formulations in animal and primate models. , 2001, Vaccine.

[17]  S. Rosenberg,et al.  CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Speiser,et al.  CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  Steven A. Rosenberg,et al.  Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution , 2001, Journal of immunotherapy.

[20]  D. Speiser,et al.  Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma , 2000, The Journal of Immunology.

[21]  A. Osterhaus,et al.  A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. , 2000, Vaccine.

[22]  D. Jäger,et al.  Vaccination for Malignant Melanoma: Recent Developments , 2000, Oncology.

[23]  J. Schlom,et al.  Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule , 2000, Cancer Immunology, Immunotherapy.

[24]  D. Jäger,et al.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Sjölander,et al.  Induction of lymphocyte recruitment in the absence of a detectable immune response. , 2000, Vaccine.

[26]  B. Fox,et al.  Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy1 , 2000, The Journal of Immunology.

[27]  V Brusic,et al.  NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. , 2000, Cancer research.

[28]  D. Speiser,et al.  Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. , 2000, Cancer research.

[29]  F. Gudat,et al.  NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens , 2000, British Journal of Cancer.

[30]  O. Tsitsilonis,et al.  Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor , 2000, Journal of Immunology.

[31]  Yao-Tseng Chen,et al.  CT10: A new cancer‐testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational‐difference analysis , 2000, International journal of cancer.

[32]  D. Jäger,et al.  Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma , 2000, The Journal of experimental medicine.

[33]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[34]  F. Lemonnier,et al.  An HLA-A2 polyepitope vaccine for melanoma immunotherapy. , 1999, Journal of Immunology.

[35]  D. Jäger,et al.  Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. , 1999, International journal of cancer.

[36]  F. Ennis,et al.  Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). , 1999, Virology.

[37]  P. Ricciardi-Castagnoli,et al.  Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.

[38]  J. Bates,et al.  Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines. , 1998, Vaccine.

[39]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[40]  M. Rolph,et al.  Recombinant viruses as vaccines and immunological tools. , 1997, Current opinion in immunology.

[41]  F. Lemonnier,et al.  HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice , 1997, The Journal of experimental medicine.

[42]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  P. Matzinger,et al.  Is cancer dangerous to the immune system? , 1996, Seminars in immunology.

[44]  D. Moss,et al.  Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720) , 1995, Journal of virology.